Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00251225 · ClinicalTrials.gov registry record · Phase 2

A Study of Imatinib and Docetaxel in Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Leonard Appleman.

Completed
Registry status
Phase 2
Development phase
49
Enrollment target
1
Study location

NCT00251225 is a Phase 2 study of Prostate Cancer that has completed, run by Leonard Appleman. The registered enrollment target is 49 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00251225, a Phase 2 study of Prostate Cancer, has completed, sponsored by Leonard Appleman.

COMPLETED
Registry status
Phase 2
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effectiveness of two drugs, docetaxel and Gleevec®(also called imatinib), in prostate cancer that no longer responds to hormone therapy. The investigators are interested in finding out if the combination of these two drugs is more effective than docetaxel alone in the treatment of prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Gleevec

Study Locations (1)

Pennsylvania

  • Hillman Cancer Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2005-08
Est. Completion 2014-03
Phase Phase 2

Sponsor

Leonard Appleman

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00251225

The ClinicalTrials.gov registry entry for NCT00251225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Leonard Appleman, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.

NCT00251225 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00251225 about?

NCT00251225 is a clinical study titled "A Study of Imatinib and Docetaxel in Prostate Cancer". The purpose of this study is to determine the effectiveness of two drugs, docetaxel and Gleevec®(also called imatinib), in prostate cancer that no longer responds to hormone therapy. The investigators are interested in finding out if the combination of these two drugs is more effective than docetaxe...

What is the current status of trial NCT00251225?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2005-08. Estimated completion is 2014-03.

What conditions does trial NCT00251225 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00251225?

The interventions under investigation include: Docetaxel (DRUG), Gleevec (DRUG).

Who is sponsoring clinical trial NCT00251225?

This trial is sponsored by Leonard Appleman, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00251225 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.